Outcomes of Stem Cells for Cerebral Palsy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02574923 |
Recruitment Status :
Completed
First Posted : October 14, 2015
Last Update Posted : May 7, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cerebral Palsy | Biological: Autologous Bone Marrow Mononuclear Cells | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 30 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Outcomes of Autologous Bone Marrow Mononuclear Cells for Cerebral Palsy: A Self-Controlled Clinical Trial |
Actual Study Start Date : | November 5, 2015 |
Actual Primary Completion Date : | March 30, 2018 |
Actual Study Completion Date : | April 30, 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: Stem cell transplantation
2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 3 months afterward
|
Biological: Autologous Bone Marrow Mononuclear Cells
Transplantation of Autologous Bone Marrow Mononuclear Cells |
- Change in Total Score of Gross Motor Function Measure (GMFM)-88 [ Time Frame: 3 months and 6 months after transplantation ]GMFM-88
- Change in Gross Motor Function Measure (GMFM)-66 Percentile [ Time Frame: 3 months and 6 months after transplantation ]GMFM-66 percentile
- Change in Muscle tone [ Time Frame: 3 months and 6 months after transplantation ]Muscle tone are assessed by Modified Ashworth Scale
- Number of adverse events [ Time Frame: Through study completion, an average of 6 months ]Examples of adverse events to look for: anaphylaxis, allergy, respiratory distress, fever, infections, vomit, epilepsy
- Change in Denver Developmental Score [ Time Frame: 3 months and 6 months after transplantation ]Denver II
- Change in Quality of Life [ Time Frame: 3 months and 6 months after transplantation ]Quality of life questionnaire for cerebral palsy (CPQOL)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 2 Years to 15 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Cerebral palsy of any types caused by oxygen deprivation.
Exclusion Criteria:
- Epilepsy
- Hydrocephalus with ventricular drain
- Coagulation disorders
- Allergy to anesthetic agents
- Severe health conditions such as cancer, failure of heart, lung, liver or kidney
- Active infections

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02574923
Vietnam | |
Vinmec International Hospital | |
Hanoi, Vietnam |
Study Chair: | Liem T Nguyen, MD., PhD. | Vinmec Healthcare System |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Vinmec Healthcare System |
ClinicalTrials.gov Identifier: | NCT02574923 |
Other Study ID Numbers: |
TBG 002 |
First Posted: | October 14, 2015 Key Record Dates |
Last Update Posted: | May 7, 2018 |
Last Verified: | May 2018 |
Cerebral Palsy Stem Cells |
Paralysis Cerebral Palsy Neurologic Manifestations Nervous System Diseases |
Brain Damage, Chronic Brain Diseases Central Nervous System Diseases |